Strategic Advocates’s TherapeuticsMD TXMD Stock Holding History

Strategic Advocates’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$2	–	585
2025 Q4	$2	Hold	1	–	–	﹤0.01%	637
2025 Q3	$1	Buy	+1	New	+$1	﹤0.01%	613

Other funds holding TXMD

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's TXMD Position: Q1 2026 in Review

Strategic Advocates sold out of TherapeuticsMD (TXMD) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Strategic Advocates first reported a position in TXMD in Q3 2025 and held it in 2 quarters. The position peaked at $2 in Q4 2025. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

Strategic Advocates reported no remaining TherapeuticsMD position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 1 TherapeuticsMD share in Q1 2026, an estimated $2.
Strategic Advocates first reported a position in TherapeuticsMD in Q3 2025 and held it in 2 quarters.
Strategic Advocates's TherapeuticsMD position peaked at $2 in Q4 2025.
49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.